GATE BT 2013 • Q4
MCQ • 1 Mark
Section 2: General Biotechnology
Cell structure and signaling
Subtopic: Fundamentals of Cell structure and signaling
Question Statement:
The first humanized monoclonal antibody approved for the treatment of breast canceris
(A) Rituximab (B) Cetuximab (C) Bevacizumab (D) Herceptin
Options:
-
(A) Rituximab
-
(B) Cetuximab
-
(C) Bevacizumab
-
(D) Herceptin
Step-by-Step Solution & Explanation
### **Official Solution & Step-by-Step Derivation (GATE BT 2013 Q.4)**
**1. Governing Concept & Syllabus Classification**:
- **Section**: BT
- **Question Type**: **MCQ** (1 Mark)
- **Core Topic**: Quantitative & Analytical Aptitude
**2. Detailed Step-by-Step Analytical & Scientific Derivation**:
- **Systematic Conceptual & Option-by-Option Evaluation**:
- Problem Focus: *"The first humanized monoclonal antibody approved for the treatment of breast canceris..."*
- **Option (D) [CORRECT]**: *"Herceptin"*
- Validated by canonical biochemistry/biotechnology literature. Specifically matches the molecular mechanism, kinetic model, or empirical finding required.
- **Option (A) [INCORRECT]**: *"Rituximab"* does not satisfy the precise boundary conditions or molecular specificity.
- **Option (B) [INCORRECT]**: *"Cetuximab"* does not satisfy the precise boundary conditions or molecular specificity.
- **Option (C) [INCORRECT]**: *"Bevacizumab"* does not satisfy the precise boundary conditions or molecular specificity.
**3. Final Answer / Verification Summary**:
- **Official GATE Answer Key**: **D**
- **Scoring Criteria**: 1 Mark (Negative marking: -0.33 marks).
Practice This in Real CBT Exam Interface
Test yourself with the official TCS-iON palette, virtual calculator, and immediate performance analytics.
Launch CBT Mock Test